{"nctId":"NCT00344370","briefTitle":"Follow-On Study of Pitavastatin Versus Atorvastatin in Patients With Type II Diabetes Mellitus and Combined Dyslipidemia","startDateStruct":{"date":"2006-08"},"conditions":["Type II Diabetes Mellitus","Dyslipidemia"],"count":214,"armGroups":[{"label":"Pitavastatin","type":"EXPERIMENTAL","interventionNames":["Drug: Pitavastatin"]},{"label":"Atorvastatin","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Atorvastatin"]}],"interventions":[{"name":"Pitavastatin","otherNames":["Livalo"]},{"name":"Atorvastatin","otherNames":["Lipitor"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Type II diabetes mellitus\n* Combined dyslipidemia\n* Completed NK-104-305 (NCT00309751)\n\nExclusion Criteria:\n\n* Withdrawal from NK-104-305 (NCT00309751)","healthyVolunteers":false,"sex":"ALL","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"NCEP LDL-C Target Attainment","description":"Number of patients attaining National Cholesterol Education Program (NCEP) LDL-C target at 44 weeks. According to NCEP criteria the target LDL-C is 100 mg/dL for all patients in this study.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"110","spread":null},{"groupId":"OG001","value":"55","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in LDL-C","description":"Percent change from baseline in LDL-C at 44 weeks","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-40.98","spread":"19.053"},{"groupId":"OG001","value":"-41.43","spread":"21.159"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":8,"n":143},"commonTop":["Naspopharyngitis","Myalgia/myalgia intercostal","Arteriosclerosis","Diabetes mellitus inadequate control"]}}}